Publicaciones científicas

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

01-jun-2021 | Revista: Clinical Lymphoma Myeloma Leukemia

Paula Rodriguez-Otero  1 , Maialen Sirvent  2 , Ana Pilar González-Rodríguez  3 , Esperanza Lavilla  4 , Alfonso García de Coca  5 , José María Arguiñano  6 , Josep M Martí  7 , Valentin Cabañas  8 , Cristina Motlló  9 , Erik de Cabo  10 , Cristina Encinas  11 , Ilda Murillo  12 , Jose Ángel Hernández-Rivas  13 , Ernesto Pérez-Persona  14 , Felipe Casado  15 , Antonia Sampol  16 , Ricarda García  17 , María Jesús Blanchard  18 , Magdalena Anguita  19 , Ana Paz Lafuente  20 , Belén Iñigo  21 , Aurelio López  22 , Paz Ribas  23 , Mario Arnao  24 , Roberto Maldonado  25 , Joan Bladé  26 , María Victoria Mateos  27 , Juan José Lahuerta  28 , Jesús F San Miguel  29

Introduction: Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide. Indeed, with currently approved treatments, median progression-free survival (PFS) in the lenalidomide-refractory setting is less than 10 months, reflecting the difficulty in treating this patient population.

Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations.

Patients and methods: A real-world study was conducted by the Spanish Myeloma group in a cohort of patients with RRMM treated with pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex). One hundred patients were treated with a median of 3 prior lines of therapy.

Results: Overall response rate was 39%, with a clinical benefit rate of 93%. Median PFS was 7.6 months; median overall survival (OS) was 12.6 months. Median PFS and OS survival were consistent across the different subgroups analyzed. Prolonged PFS and OS were found in patients with responsive disease.

Conclusion: Our results compared favorably with those obtained with different pomalidomide-based combinations in a similar patient population. PomCiDex remains a manageable, cost-effective, and all-oral triplet combination for RRMM patients.

CITA DEL ARTÍCULO  Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):413-420.  doi: 10.1016/j.clml.2021.02.004. Epub 2021 Feb 16.

Nuestros autores